Expression of cytochrome P450 2A5 in preneoplastic and neoplastic mouse liver lesions

Molecular Carcinogenesis

Volumn 22, Issue 4, 1998, Pages 229-234

  Wastl, Ute M ^a   Rossmanith, Walter ^a   Lang, Matti A ^b,c   Camus Randon, Anne Marie ^b   Grasl Kraupp, Bettina ^a   Bursch, Wilfried ^a   Schulte Hermann, Rolf ^a,d  

^a UNIVERSITY OF VIENNA   (Austria)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c UPPSALA UNIVERSITY   (Sweden)

^d Inst of Tum Biol and Cancer Res   (Austria)

Author keywords

Carcinogenesis; Gene expression; Tumor marker

Indexed keywords

CYTOCHROME P450;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; GENE EXPRESSION REGULATION; LIVER CANCER; LIVER CARCINOGENESIS; LIVER METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOBIOTIC METABOLISM;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; CARCINOGENS; CYTOCHROME P-450 ENZYME SYSTEM; DIETHYLNITROSAMINE; DISEASE PROGRESSION; DISEASE SUSCEPTIBILITY; ENZYME INDUCTION; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MIXED FUNCTION OXYGENASES; PHENOBARBITAL; PRECANCEROUS CONDITIONS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

ANIMALIA;

EID: 0031853832     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199808)22:4<229::AID-MC4>3.0.CO;2-E     Document Type: Article

References (32)

1. Schulte-Hermann R. Tumor promotion in the liver. Arch Toxicol 57:147-158, 1985.
2. Pilot HC. Altered hepatic foci: Their role in murine hepatocarcinogenesis. Annu Rev Pharmacol Toxicol 30:465-500, 1990.
3. Farber E, Cameron R. The sequential analysis of cancer development. Adv Cancer Res 31:125-226, 1980.
4. Satoh K, Kitahara A, Soma Y, Inaba Y, Hatayama I, Sato K. Purification, induction, and distribution of placental glutathione transferase: A new marker enzyme for preneoplastic cells in the rat chemical hepatocarcinogenesis. Proc Natl Acad Sci USA 82:3964-3968, 1985.
5. Pitot HC, Barsness L, Goldsworthy T, Kitagawa T. Biochemical characterization of stages of hepatocarcinogenesis after a single dose of diethylnitrosamine. Nature 271:456-458, 1978.
6. Ohmori T, Rice JM, Williams GM. Histochemical characteristics of spontaneous and chemically induced hepatocellular neoplasms in mice and the development of neoplasms with γ-glutamyl transpeptidase activity during phenobarbital exposure. Histochem J 13:85-99, 1981.
7. Buchmann A, Bock KW, Schwarz M. Enzyme and immunohistochemical phenotypmg of diethylnitrosamine-induced liver lesions of male C3H/He, B6C3F1 and C57BL/6J mice. Carcinogenesis 13:691-697, 1992.
8. Nakano H, Hatayama I, Satoh K, Suzuki S, Sato K, Tsuchida S. c-jun expression in single cells and preneoplastic foci induced by diethylnitrosamine in B6C3F1 mice: Comparison with the expression of pi-class glutathione S-transferase. Carcinogenesis 15:1853-1857, 1994.
9. Moore MR, Drinkwater NR, Miller EC, Miller JA, Pitot HC. Quantitative analysis of the time-dependent development of glucose-6-phosphatase-deficient foci in the livers of mice treated neonatally with diethylnitrosamine. Cancer Res 41:1585-1593, 1981.
10. Vesselinovitch SD, Hacker HJ, Bannasch P. Histochemical characterization of focal hepatic lesions induced by single diethylnitrosamine treatment in infant mice. Cancer Res 45:2774-2780, 1985.
11. 15α) in liver and kidney of male mice by androgen. J Biol Chem 263:4166-4171, 1988.
12. Negishi M, Lindberg R, Burkhart B, Ichikawa T, Honkakoski P, Lang MA. Mouse steroid 15 alpha-hydroxylase gene family: Identification of type II P-450(15)alpha as coumarin 7-hydroxylase. Biochemistry 28:4169-4172, 1989.
13. Lang MA, Juvonen RO, Järvinen P, Honkakoski P, Raunio H. Mouse liver P450Coh: Genetic regulation of the pyrazole-inducible enzyme and comparison with other P450 isozymes. Arch Biochem Biophys 271:139-148, 1989.
14. Camus A-M, Geneste O, Honkakoski P, et al. High variability of nitrosamine metabolism among individuals. Role of cytochromes P450 2A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodiethylamine in mice and humans. Mol Carcinog 7:268-275, 1993.
15. Pelkonen P, Lang MA, Wild CP, Negishi M, Juvonen RO. Activation of aflatoxin B1 by mouse CYP2A enzymes and cytotoxicity in recombinant yeast cells. Eur J Pharmacol 292:67-73, 1994.
16. Pellinen P, Stenbäck F, Rautio A, Pelkonen O, Lang M, Pasanen M. Response of mouse liver coumarin 7-hydroxylase activity to hepatotoxins: Dependence on strain and agent and comparison to other monooxygenases. Naunyn Schmiedebergs Arch Pharmacol 348:435-443, 1993.
17. Salonpää P, Krause K, Pelkonen O, Raunio H. Up-regulation of CYP2A5 expression by porphyrinogenic agents in mouse liver. Naunyn Schmiedebergs Arch Pharmacol 351:446-452, 1995.
18. Knasmüller S, Parzefall W, Helma C, Kassie F, Ecker S, Schulte-Hermann R. Toxic effects of griseofulvin: Disease models, mechanisms, and risk assessment. Crit Rev Toxicol, in press.
19. Camus-Randon A-M, Raffalli F, Béréziat J-C, McGregor D, Konstandi M, Lang MA. Liver injury and expression of cytochromes P450: Evidence that regulation of CYP2A5 is different from that of other major xenobiotic metabolizing CYP enzymes. Toxicol Appl Pharmacol 138:140-148, 1996.
20. Kirby GM, Chemin I, Montesano R, Chisari FV, Lang MA, Wild CP. Induction of specific cytochrorne P450s involved in aflatoxin BI metabolism in hepatitis B virus transgenic mice. Mol Carcinog 11:74-80, 1994.
21. Kirby GM, Pelkonen P, Vatanasapt V, Camus A-M, Wild CP, Lang MA. Association of liver fluke (Opisthorchis viverrni) infestation with increased expression of cytochrorne P450 and carcinogen metabolism in male hamster liver. Mol Carcinog 11:81-89, 1994.
22. Kobliakov V, Kulikova L, Samoilov D, Lang MA. High expression of cytochrome P450 2a-5 (coumarin 7-hydroxylase) in mouse hepatomas. Mol Carcinog 7:276-280, 1993.
23. Lange E, Ducloux N, Périn F, Larroque C, van Lier LE, Zajdela F. Particular cytochrome P-450-dependent steroid metabolism: A new class of mouse liver tumor markers. Carcinogenesis 10:1871-1877, 1989.
24. Satarug S, Lang MA, Yongvanit P, et al. Induction of cytochrome P450 2A6 expression in humans by the carcinogenic parasite infection, Opisthorchiasis viverrni. Cancer Epidemiol Biomarkers Prev 5:795-800, 1996.
25. Grasso P, Hardy J. Strain difference in natural incidence and response to carcinogens. In: Butler WH, Newberne PM (eds), Mouse Hepatic Neoplasia. Elsevier, Amsterdam, 1975, pp. 111-132.
26. Frith CH, Ward JM. A morphologic classification of proliferative and neoplastic hepatic lesions in mice. J Environ Pathol Toxicol 3:329-351, 1979.
27. Maronpot RR, Haseman JK, Boorman GA, Eustis SE, Rao GN, Huff JE. Liver lesions in B6C3F1 mice: The National Toxicology Program, experience and position. Arch Toxicol Suppl 10:10-26, 1987.
28. Raunio H, Juvonen R, Pasanen M, Pelkonen O, Paakko, Soini Y. Cytochrorme P4502A6 (CYP2A6) expression in human hepatocellular carcinoma. Hepatology 27:427-432, 1998.
29. Geneste O, Raffalli F, Lang MA. Identification and characterization of a 44 kDa protein that binds to the 3′-untranslated region of CYP2a5 mRNA: Inducibility, subcellular distribution and possible role in mRNA stabilization. Biochem J 313:1029-1037, 1996.
30. Becker FF, Stout DL. A constitutive deficiency in the mono-oxygenase system of spontaneous mouse liver tumors. Carcinogenesis 5:785-788, 1984.
31. Schulte-Hermann R, Roome N, Timmermann-Trosiener I, Schuppler J. Immunocytochemical demonstration of a phenobarbital-inducible cytochrome P450 in putative preneoplastic foci of rat liver. Carcinogenesis 5:149-153, 1984.
32. Schulte-Hermann R, Timmermann-Trosiener I, Schuppler J. Facilitated expression of adaptive responses to phenobarbital in putative pre-stages of liver cancer. Carcinogenesis 7:1651-1655, 1986.